Serum interleukin-12 levels in patients with multiple sclerosis

J. Drulović, M. Mostarica-Stojković, Z. Lević, S. Mesaroš, N. Stojsavljević, D. Popadić, V. Pravica

    Research output: Contribution to journalArticlepeer-review


    Increasing body of evidence which suggests a crucial role for interleukin (IL)-12 in modulating immune responses in multiple sclerosis (MS) prompted us to analyze IL-12 in serum from MS patients. We measured the sera concentrations of IL-12, tumor necrosis factor (TNF)-α and transforming growth factor-β1, in 21 MS patients and 13 patients with non-inflammatory nervous diseases. In clinically active MS, serum levels of IL-12 were detectable in 53% and TNF-α in 40% of patients. None of the patients with clinically inactive MS had detectable IL-12 and TNF-α sera levels. Analysis of serum concentrations of all three cytokines revealed no significant differences between MS patients and controls. These findings provide further evidence that both IL-12 and TNF-α might have an active role in immunopathogenesis of MS.
    Original languageEnglish
    Pages (from-to)129-132
    Number of pages3
    JournalNeuroscience letters
    Issue number2
    Publication statusPublished - 24 Jul 1998


    • Interleukin-12
    • Multiple sclerosis
    • Serum
    • Transforming growth factor-β
    • Tumor necrosis factor-α


    Dive into the research topics of 'Serum interleukin-12 levels in patients with multiple sclerosis'. Together they form a unique fingerprint.

    Cite this